Conditions: Prostate Cancer
Keywords: Hormone-refractory prostate cancer multitargeted tyrosinkinase
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 67
Healthy volunteers: no

Brief summary:
The purpose of this study is to evaluate the efficacy, tolerability and safety of a multi-targeted therapy in patients with hormone-refractory prostate cancer.

Detailed description:

Arms:
arm 1: STI571 (imatinib) 400mg po daily + pioglitazone 60mg po daily + etoricoxib 60mg po daily + dexamethasone 1mg po daily + treosulfane 500mg po daily for 24 weeks

Interventions: intervention 1: imatinib mesylate intervention 2: Treosulfane intervention 3: etoricoxib intervention 4: pioglitazone intervention 5: dexamethasone
Intervention descriptions: intervention 1: None intervention 2: None intervention 3: None intervention 4: None intervention 5: None

Protocol document: